Transgenomic Launches New Cancer Detection Test
Transgenomic announced Monday the launch of its Multiplexed Ice Cold PCR CLIA test for cancer mutation detection. The first tests released are for non-small cell lung and colorectal cancer mutations. The Omaha, Neb., company plans to unveil tests more for additional cancers in the next few months.
MX ICP technology enables high-sensitivity detection by enriching and amplifying limited quantities of mutant DNA sequences, which allows for a 500-fold increase in detection sensitivity, the devicemaker claims.
The test can accept patient samples such as tissue, plasma, fine needle aspiration, bronchoscopy, cytology and other body fluid samples, with results available in seven to 10 business days. Importantly, the kit provides an alternative means of testing for those unable to undergo a biopsy.
Transgenomic offers diagnostic products for cardiology, oncology and inherited diseases. — Jason Scott